๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2025-10-27

5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy (NCT04288427)

๐ŸŸข Recruiting Observational / Diagnostic ๐Ÿ’Š Investigational Drug / Biologic Sponsor: Beth Israel Deaconess Medical Center

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

The study is being conducted to learn why some patients with Benign Prostatic Hyperplasia (BPH) do not respond to a commonly used treatment drug, Finasteride. The hope is to find ways to predict which patients will not respond to Finasteride so that, in the future, these patients can be identified prior to offering this treatment and they can be offered alternative treatment strategies in its place. The aim is to see if noninvasive techniques such as MRI can detect inflammation of the prostate to assist with early detection of those who will and who will not respond to Finasteride.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (8 items).

Location: Beth Israel Deaconess Medical Center โ€” Boston, Massachusetts

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Diagnosis of any prostatic malignancy or precancerous lesions (atypical glandular foci and prostatic intraepithelial neoplasia);
  • Treatment with 5ARI (Finasteride or Dutasteride) within six months of study enrollment;
  • Current urinary tract infection;
  • Previous pelvic radiation;
  • Previous treatment with demethylating drugs;
  • Diagnosis of multiple sclerosis, Alzheimer's, Parkinson's, neurological deficits in the judgment of the investigator;
  • Unable or unwilling to undergo MRI due to implants, claustrophobia, etc.

๐Ÿ” Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

๐Ÿ“ All Participating Trial Locations (1 Sites)

  • Beth Israel Deaconess Medical Center โ€” Boston, Massachusetts

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
๐Ÿ›๏ธ View Official NIH Record โ†—